AbbVie Inc (ABBV)

neg -0.95
Today's Range: 59.36 - 60.99 | ABBV Avg Daily Volume: 14,196,000
Last Update: 10/29/14 - 4:00 PM EDT
Volume: 16,547,937
YTD Performance: 13.58%
Open: $60.99
Previous Close: $60.93
52 Week Range: $45.50 - $61.13
Oustanding Shares: 1,591,699,124
Market Cap: 96,982,227,625
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 5 5 5
Moderate Buy 1 0 0 0
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.50 1.57 1.57 1.57
Latest Dividend: 0.49
Latest Dividend Yield: 3.22%
Dividend Ex-Date: 01/13/15
Price Earnings Ratio: 23.62
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
23.62 13.20 27.09
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
12.26% 20.47% 0.00%
Revenue 5.40 0.00 0.00
Net Income 53.70 0.00 0.00
EPS 0.00 0.00 0.00
Earnings for ABBV:
Revenue 18.38B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $0.77 $0.88 $3.17 $4.10
Number of Analysts 4 3 9 9
High Estimate $0.79 $0.92 $3.23 $4.65
Low Estimate $0.76 $0.86 $3.10 $3.70
Prior Year $0.82 $0.82 $3.14 $3.17
Growth Rate (Year over Year) -5.49% 7.72% 0.96% 29.44%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Oct 22, 2014 | 7:21 AM EDT
ABBV estimates were raised through 2015, BMO Capital said. Expect the company to exceed consensus and Hep-C can drive future growth. Ou...
There is virtually no room for error in a crowded trade.
We now have an investable bottom on our hands.
It's unlikely that they will be hit by Europe or the Ebola scare. 
There will likely be more selling until the elusive bottom is reached.

This Morning's Market Setup Real Money Pro($)

 Where it began.
The two tech giants help women freeze their eggs.
We are buying the weakness, albeit slowly.
Jul 28, 2014 | 8:03 AM EDT
ABBV was upgraded to Buy from Neutral, UBS said. Reflective of accretive Shire deal. $67 price target. 
Jul 23, 2014 | 7:41 AM EDT
ABBV was placed on the US 1 list, according to Bank of America/Merrill Lynch said. Estimates also increased, given higher expected Hepa...

Columnist Conversations

Based on Wednesday's roughly 1972 day session close, overnight inventory is predominately held short. Failure ...
There was an article yesterday with comments by former Fed Chair Alan Greenspan as he came out criticizing rec...
Over the last couple of weeks we have witnessed an historic rise then fall of short term volatility. Much of ...
Both life insurers record beats to expectations. My view, already discounted in share prices. More to come.


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.